Arax Advisory Partners’s Medifast MED Stock Holding History

Arax Advisory Partners’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$79.3K	Buy	7,470 +6,692	+860%	+$77.2K	﹤0.01%	2899
2026 Q1	$7.93K	Sell	778 -10,819	-93%	-$117K	﹤0.01%	2571
2025 Q4	$1.84K	Buy	11,597 +5,356	+86%	+$64.1K	﹤0.01%	3291
2025 Q3	$85.4K	Buy	6,241 +5,825	+1,400%	+$81.4K	﹤0.01%	1592
2025 Q2	$5.84K	Buy	416 +371	+824%	+$4.88K	﹤0.01%	2184
2025 Q1	$607	Buy	45 +2	+5%	+$30	﹤0.01%	2499
2024 Q4	$759	Sell	43 -1,575	-97%	-$29.2K	﹤0.01%	2227
2024 Q3	$31K	Buy	1,618 +728	+82%	+$14K	﹤0.01%	909
2024 Q2	$19.4K	Buy	+890	New	+$23.7K	﹤0.01%	976
2024 Q1	–	Sell	-6	Closed	-$404	–	1364
2023 Q4	$404	Buy	+6	New	+$418	﹤0.01%	1239
2023 Q2	–	Sell	-51	Closed	-$5.29K	–	1299
2023 Q1	$5.29K	Hold	51	–	–	﹤0.01%	839
2022 Q4	$5.88K	Hold	51	–	–	﹤0.01%	747
2022 Q3	$6K	Hold	51	–	–	﹤0.01%	753
2022 Q2	$9K	Hold	51	–	–	﹤0.01%	668
2022 Q1	$9K	Hold	51	–	–	﹤0.01%	670
2021 Q4	$11K	Hold	51	–	–	﹤0.01%	637
2021 Q3	$10K	Hold	51	–	–	﹤0.01%	641
2021 Q2	$14K	Buy	+51	New	+$13.8K	﹤0.01%	618
2020 Q4	$10K	Buy	+51	New	+$9.01K	﹤0.01%	569

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arax Advisory Partners's MED Position: Q2 2026 in Review

Arax Advisory Partners increased its Medifast (MED) stake by 860% in Q2 2026, buying an estimated $77.2K and bringing the position to 7,470 shares worth $79.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2899.

Arax Advisory Partners first reported a position in MED in Q4 2020 and has held it in 19 quarters since. The position peaked at $85.4K in Q3 2025. 113 funds tracked by Wall St. Rank hold MED as of Q2 2026.

Arax Advisory Partners held 7,470 shares of Medifast worth $79.3K as of Q2 2026.
Arax Advisory Partners bought 6,692 Medifast shares in Q2 2026, an estimated $77.2K.
Medifast made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2899 holding.
Arax Advisory Partners first reported a position in Medifast in Q4 2020 and has held it in 19 quarters since.
Arax Advisory Partners's Medifast position peaked at $85.4K in Q3 2025.
113 funds tracked by Wall St. Rank held Medifast as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.